Supplementary Tables from The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care
posted on 2023-03-31, 20:10authored byTeresa Paíno, Antonio Garcia-Gomez, Lorena González-Méndez, Laura San-Segundo, Susana Hernández-García, Ana-Alicia López-Iglesias, Esperanza M. Algarín, Montserrat Martín-Sánchez, David Corbacho, Carlos Ortiz-de-Solorzano, Luis A. Corchete, Norma C. Gutiérrez, María-Victoria Maetos, Mercedes Garayoa, Enrique M. Ocio
-Supplementary Table 1. Combination indices (CI) corresponding to the indicated double or triple combinations of PIM447, bortezomib and dexamethasone. -Supplementary Table 2. Combination indices (CI) corresponding to the indicated double or triple combinations of PIM447, lenalidomide and dexamethasone. -Supplementary Table 3. Combination indices (CI) corresponding to the indicated double or triple combinations of PIM447, pomalidomide and dexamethasone.